Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Pier Capital LLC

Pier Capital LLC grew its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 97.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 332,319 shares of the company's stock after acquiring an additional 164,237 shares during the quarter. Pier Capital LLC owned about 0.23% of Denali Therapeutics worth $6,773,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in DNLI. Quest Partners LLC purchased a new stake in Denali Therapeutics in the 3rd quarter worth about $73,000. PNC Financial Services Group Inc. lifted its stake in shares of Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after acquiring an additional 885 shares during the last quarter. KBC Group NV boosted its holdings in Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after acquiring an additional 2,731 shares during the period. AlphaQuest LLC grew its position in Denali Therapeutics by 177.1% in the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock valued at $142,000 after acquiring an additional 4,449 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in Denali Therapeutics by 32.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after purchasing an additional 2,436 shares during the period. Institutional investors own 92.92% of the company's stock.

Remove Ads

Insider Transactions at Denali Therapeutics

In related news, insider Carole Ho sold 12,255 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the transaction, the insider now owns 178,580 shares in the company, valued at $3,610,887.60. This trade represents a 6.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Ryan J. Watts sold 29,266 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares in the company, valued at approximately $5,271,778.62. The trade was a 10.09 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,940 shares of company stock worth $973,442. Insiders own 7.90% of the company's stock.

Denali Therapeutics Stock Performance

DNLI traded up $0.58 during trading on Friday, hitting $14.78. The stock had a trading volume of 1,513,530 shares, compared to its average volume of 1,024,755. The stock has a 50 day simple moving average of $19.05 and a two-hundred day simple moving average of $23.23. The company has a market capitalization of $2.15 billion, a PE ratio of -5.36 and a beta of 1.46. Denali Therapeutics Inc. has a twelve month low of $13.67 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on DNLI shares. William Blair reaffirmed an "outperform" rating on shares of Denali Therapeutics in a research note on Friday, February 28th. HC Wainwright boosted their price target on Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a report on Friday, February 28th. Oppenheimer reduced their price objective on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Bank of America lowered their target price on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a report on Monday, March 10th. Finally, Morgan Stanley initiated coverage on Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 price target on the stock. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $37.20.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.